ATM, ATR, CHK1, CHK2 and WEE1 Inhibitors in Cancer and Cancer Stem Cells

Overview

Journal Medchemcomm

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2018 Aug 16

PMID 30108746

Citations 48

Authors

Cyril Ronco

Anthony R Martin

Luc Demange

Rachid Benhida

Affiliations

Soon will be listed here.

Abstract

DNA inevitably undergoes a high number of damages throughout the cell cycle. To preserve the integrity of the genome, cells have developed a complex enzymatic machinery aimed at sensing and repairing DNA lesions, pausing the cell cycle to provide more time to repair, or induce apoptosis if damages are too severe. This so-called DNA-damage response (DDR) is yet considered as a major source of resistance to DNA-damaging treatments in oncology. Recently, it has been hypothesized that cancer stem cells (CSC), a sub-population of cancer cells particularly resistant and with tumour-initiating ability, allow tumour re-growth and cancer relapse. Therefore, DDR appears as a relevant target to sensitize cancer cells and cancer stem cells to classical radio- and chemotherapies as well as to overcome resistances. Moreover, the concept of synthetic lethality could be particularly efficiently exploited in DDR. Five kinases play pivotal roles in the DDR: ATM, ATR, CHK1, CHK2 and WEE1. Herein, we review the drugs targeting these proteins and the inhibitors used in the specific case of CSC. We also suggest molecules that may be of interest for preclinical and clinical researchers studying checkpoint inhibition to sensitize cancer and cancer stem cells to DNA-damaging treatments.

Citing Articles

Synergistic effect of inhibiting CHK2 and DNA replication on cancer cell growth.

Coquel F, Ho S, Tsai K, Yang C, Aze A, Devin J Elife. 2025; 13.

PMID: 39887032 PMC: 11785374. DOI: 10.7554/eLife.104718.

Dissociation of the nuclear WWOX/TRAF2 switch renders UV/cold shock-mediated nuclear bubbling cell death at low temperatures.

Chen S, Tsai C, Lin S, Lee M, Huang S, Zeng H Cell Commun Signal. 2024; 22(1):505.

PMID: 39420317 PMC: 11487720. DOI: 10.1186/s12964-024-01866-6.

Circadian clocks in health and disease: Dissecting the roles of the biological pacemaker in cancer.

Fortin B, Mahieu A, Fellows R, Pannunzio N, Masri S F1000Res. 2024; 12:116.

PMID: 39282509 PMC: 11399774. DOI: 10.12688/f1000research.128716.2.

Enhanced pharmacological activities of AKR1C3-activated prodrug AST-3424 in cancer cells with defective DNA repair.

Meng F, Qi T, Liu X, Wang Y, Yu J, Lu Z Int J Cancer. 2024; 156(2):417-430.

PMID: 39243400 PMC: 11578084. DOI: 10.1002/ijc.35170.

GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer.

Drainas A, Hsu W, Dallas A, Poltorack C, Kim J, He A Cell Rep. 2024; 43(8):114606.

PMID: 39120974 PMC: 11407228. DOI: 10.1016/j.celrep.2024.114606.

References

Walton M, Eve P, Hayes A, Valenti M, de Haven Brandon A, Box G . CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res. 2012; 18(20):5650-61. PMC: 3474704. DOI: 10.1158/1078-0432.CCR-12-1322. View

Massey A, Stokes S, Browne H, Foloppe N, Fiumana A, Scrace S . Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design. Oncotarget. 2015; 6(34):35797-812. PMC: 4742142. DOI: 10.18632/oncotarget.5929. View

Kim M, Koo J, Han G, Kim B, Lee Y, Ahn C . Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation. J Korean Med Sci. 2016; 31(3):360-70. PMC: 4779859. DOI: 10.3346/jkms.2016.31.3.360. View

Mak J, Man W, Chow J, Ma H, Poon R . Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells. Oncotarget. 2015; 6(25):21074-84. PMC: 4673251. DOI: 10.18632/oncotarget.4020. View

Caretti V, Hiddingh L, Lagerweij T, Schellen P, Koken P, Hulleman E . WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol Cancer Ther. 2012; 12(2):141-50. DOI: 10.1158/1535-7163.MCT-12-0735. View

Pouliot L, Chen Y, Bai J, Guha R, Martin S, Gottesman M . Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 2012; 72(22):5945-55. PMC: 3500396. DOI: 10.1158/0008-5472.CAN-12-1400. View

Pokorny J, Calligaris D, Gupta S, Iyekegbe Jr D, Mueller D, Bakken K . The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. Clin Cancer Res. 2015; 21(8):1916-24. PMC: 4401631. DOI: 10.1158/1078-0432.CCR-14-2588. View

Chen J, Shao R, Li F, Monteiro M, Liu J, Xu Z . PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Clin Exp Pharmacol Physiol. 2015; 42(12):1317-26. DOI: 10.1111/1440-1681.12493. View

Choi S, Toledo L, Fernandez-Capetillo O, Bakkenist C . CGK733 does not inhibit ATM or ATR kinase activity in H460 human lung cancer cells. DNA Repair (Amst). 2011; 10(10):1000-1. PMC: 3189494. DOI: 10.1016/j.dnarep.2011.07.013. View

10.

Yang D, Halaby M, Li Y, Hibma J, Burn P . Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discov Today. 2011; 16(7-8):332-8. DOI: 10.1016/j.drudis.2011.02.001. View

11.

Russell P, Nurse P . Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell. 1987; 49(4):559-67. DOI: 10.1016/0092-8674(87)90458-2. View

12.

Caldwell J, Welsh E, Matijssen C, Anderson V, Antoni L, Boxall K . Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J Med Chem. 2010; 54(2):580-90. DOI: 10.1021/jm101150b. View

13.

Marone R, Cmiljanovic V, Giese B, Wymann M . Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2007; 1784(1):159-85. DOI: 10.1016/j.bbapap.2007.10.003. View

14.

Restelli V, Chila R, Lupi M, Rinaldi A, Kwee I, Bertoni F . Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. Oncotarget. 2015; 6(35):37229-40. PMC: 4741926. DOI: 10.18632/oncotarget.5954. View

15.

Prevo R, Fokas E, Reaper P, Charlton P, Pollard J, McKenna W . The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012; 13(11):1072-81. PMC: 3461814. DOI: 10.4161/cbt.21093. View

16.

Chila R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A . Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget. 2014; 6(5):3394-408. PMC: 4413661. DOI: 10.18632/oncotarget.2583. View

17.

Bertrand G, Maalouf M, Boivin A, Battiston-Montagne P, Beuve M, Levy A . Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev Rep. 2013; 10(1):114-26. DOI: 10.1007/s12015-013-9467-y. View

18.

Nguyen T, Saleem R, Luderer M, Hovde S, Henry R, Tepe J . Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors. ACS Chem Biol. 2011; 7(1):172-84. DOI: 10.1021/cb200320c. View

19.

Venkatesha V, Parsels L, Parsels J, Zhao L, Zabludoff S, Simeone D . Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia. 2012; 14(6):519-25. PMC: 3394194. DOI: 10.1593/neo.12538. View

20.

Huntoon C, Flatten K, Wahner Hendrickson A, Huehls A, Sutor S, Kaufmann S . ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013; 73(12):3683-91. PMC: 3687010. DOI: 10.1158/0008-5472.CAN-13-0110. View